SCHEMBL526468

SCHEMBL526468

NC(=O)c1nccn1N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL780236 0.82
SCHEMBL8990608 0.76 PARP1 (0.42)
SCHEMBL284637 0.76
SCHEMBL29998594 0.75 KMT2A (0.33)
Iodide SCHEMBL5464242 0.74 NAMPT (0.44)
Lithium SCHEMBL31348018 0.74 NAMPT (0.44)
SCHEMBL151256 0.71 ALDH1A1 (0.42)
SCHEMBL12410703 0.71 TTK (0.33)
SCHEMBL13496087 0.71 NNMT (0.33)
SCHEMBL3810263 0.71 ALDH1A1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250082652-A1 SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES UNIVERSITÄT ZU KÖLN (DE) 2025-03-13 US claimed
EP-4460301-A1 SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES Universität zu Köln (DE) 2024-11-13 EP claimed
EP-3720493-B1 COMBINATIONS OF RIPK1- AND IKK-INHIBITORS FOR THE PREVENTION OR TREATMENT OF IMMUNE DISEASES UNIV KOELN (DE) 2024-07-24 EP claimed
WO-2023131576-A1 SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES UNIVERSITÄT ZU KÖLN (DE) 2023-07-13 WO claimed
EP-4209213-A1 SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES Universität zu Köln (DE) 2023-07-12 EP claimed
WO-2010147663-A1 METHODS AND COMPOSITIONS FOR INHIBITING PROLIFERATION OF ANEUPLOID CELLS MASSECHUSETTS INSTITUTE OF TECHNOLOGY (US) 2010-12-23 WO claimed
CN-101842095-A Formulations, methods and targets for tumor therapy MING YU 2010-09-22 CN claimed
EP-2178531-A2 METHODS, COMPOSITION, TARGETS FOR COMBINATIONAL CANCER TREATMENTS Yu, Ming (US) 2010-04-28 EP claimed
WO-2009006555-A2 METHODS, COMPOSITION, TARGETS FOR COMBINATIONAL CANCER TREATMENTS YU, MING (US) 2009-01-08 WO claimed
EP-1888060-A2 NK-B INHIBITORS FOR THE TREATMENT OF MUSCULAR DYSTROPHY A. T. Still University of Health Sciences (US) 2008-02-20 EP claimed
US-20060280812-A1 Compositions and methods for the treatment of muscular dystrophy A.T. STILL UNIVERSITY OF HEATH SCIENCES 2006-12-14 US claimed
WO-2006127930-A2 NK-B INHIBITORS FOR THE TREATMENT OF MUSCULAR DYSTROPHY A. T. STILL UNIVERSITY OF HEALTH SCIENCES (US) 2006-11-30 WO claimed
US-20030166201-A1 Selection systems for genetically modified cells CITY OF HOPE 2003-09-04 US claimed
US-20250144105-A1 CDK9 INHIBITORS ORIGENIS GMBH (DE) 2025-05-08 US disclosed
US-20250082652-A1 SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES UNIVERSITÄT ZU KÖLN (DE) 2025-03-13 US disclosed
EP-4460301-A1 SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES Universität zu Köln (DE) 2024-11-13 EP disclosed
EP-0432677-A1 N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1991-06-19 EP disclosed
US-5013738-A L-glutamic acid derivatives THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1991-05-07 US disclosed
EP-0405370-A1 Riboflavinoverproducing strains of bacteria F. HOFFMANN-LA ROCHE AG (CH) 1991-01-02 EP disclosed
US-4920125-A L-glutamic acid derivatives THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1990-04-24 US disclosed